Skip to main content Skip to footer
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc.
  • Home
  • About Us
    • Our Story
    • Our Mission, Vision, Values
    • Our Team
    • Our Partners
    • Investors & Media
  • Patients
    • About Lupus Nephritis
    • Resources
    • Patient Support Program
    • Aurinia in Action
  • Our Science
    • Our Product
    • Our Pipeline
    • Our Research and Data
  • Investors & Media
    • News & Events
    • Corporate Presentation
    • Financial Info
    • Stock Data
    • SEC Filings
    • ESG
    • Board of Directors
    • Governance
    • Investor Tools
  • Aurinia Gives
    • Aurinia Gives
    • CME Grants
    • Charitable Giving FAQs
    • Sponsorships
    • Charitable Donations
    • Patient-Centered Care Grants
  • Careers
    • Our Culture
    • Our Benefits
    • Notice to Recruiters
    • Careers Contact
    • Open Positions
  • Contact Us
    • Report an Adverse Event

Press Releases

Investors & Media

Investors & Media

  • News & Events
    • Press Releases
    • IR Calendar
    • 2025 AGM
  • Corporate Presentation
    • Corporate Presentation
  • Financial Info
    • Financial Results
  • Stock Data
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Filings
  • ESG
  • Board of Directors
  • Governance
  • Investor Tools
    • Overview
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News & Events

  • Press Releases
  • IR Calendar
  • 2025 AGM
December 5, 2022 • 4:05 pm EST

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 30, 2022 • 4:05 pm EST

Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

November 3, 2022 • 6:00 am EDT

Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results

October 28, 2022 • 5:30 pm EDT

Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022

October 27, 2022 • 12:00 pm EDT

Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022

October 25, 2022 • 7:05 am EDT

Aurinia Launches Campaign Aimed at Educating and Motivating People with Lupus Nephritis to Prioritize Their Kidney Health and Take Action

October 3, 2022 • 4:05 pm EDT

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 20, 2022 • 4:05 pm EDT

Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022

September 19, 2022 • 11:15 am EDT

Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

August 4, 2022 • 6:00 am EDT

Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • …
  • Page 35
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed

<h2>We are passionate about changing the trajectory of autoimmune diseases.<br>Join us.</h2>

Business Development

bd@auriniapharma.com

Investor Relations

ir@auriniapharma.com

Clinical Trials

clinicaltrials@auriniapharma.com

Medical Information

medinfo@auriniapharma.com

Corporate Communications and Media Inquiries

AChristopher@auriniapharma.com

Patient Safety

Report an Adverse Event
Privacy Statement Terms of Use Disclaimer Aurinia Community Guidelines Aurinia Compliance Program Manage Cookie Preferences
©2025 Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23
Back to top

Navigating away from Aurinia

You are about to leave the Aurinia Pharmaceuticals website. We are not responsible for the content or accuracy of information on any third-party websites nor do we monitor or endorse such websites. If you would like to leave the Aurinia website and visit the third-party website, please select CONTINUE.